疏肝利胆活血化瘀法联合熊去氧胆酸对原发性胆汁性肝硬化患者的临床研究
|
摘要
研究背景：原发性胆汁性肝硬化(PBC)是欧美等发达国家常见病之一,既往在我国发病率较低,但调查研究显示我国发病率呈逐年上升趋势,本病患者90%以上为35-65岁女性,男女发病比率为1：10,有明显家族聚集倾向,临床可见标志性自身抗体,免疫球蛋白升高,合并免疫系统疾病。本病病因和发病机制不明确,治疗上无法针对病因治疗,仍以对症支持治疗为主,尚缺乏特异性治疗药物。疏肝利胆活血化瘀法,从“湿热瘀毒”理论出发,基于国医大师周仲英教授治疗慢性肝病的多年临证经验,结合本病发病特点,以疏肝、清化共奏利胆之功。临证运用时在此基础上辨证加减,以达到祛邪顾正,邪去正安的功效。
研究目的：通过临床试验,观察疏肝利胆活血化瘀法联合UDCA治疗原发性胆汁性肝硬化的临床疗效,为本病的临床治疗提供有效方药。
方法：选择30例符合入选标准的PBC患者,随机分为治疗组和对照组,治疗组予以疏肝利胆活血化瘀为治法的中药联合熊去氧胆酸(优思弗)治疗,对照组予优思弗治疗,疗程为6个月,记录治疗前后两组患者症状体征、肝功能、凝血、肝纤维化等指标的变化,采用SPSS13.0进行统计学处理,对比分析疗效,评价疏肝利胆活血化瘀法的临床疗效。
结果：治疗组能明显改善患者乏力、胁痛、黄疸、皮肤瘙痒等临床症状及体征,对于ALT、ALP、TBil、GGT等肝功能指标改善作用显著,在改善患者凝血功能、肝纤维化等指标方面较对照组具有明显优势。
结论：疏肝利胆活血化瘀法治疗PBC临床疗效显著,值得进一步深入研究。
Background:Primary biliary cirrhosis (PBC) is one of the common diseases of Europe and the United States and other developed countries, the past incidence is relatively low in China, but research shows that China's incidence rate showed an increasing trend, the patients with more than90%35-65year-old female, male and female incidence ratio of1:10, there is significant familial aggregation tendency, visible clinical signs of autoantibodies, elevated immunoglobulin combined immune system diseases, the etiology and pathogenesis of this disease is not clear, the treatment can not betreatment for the cause is still symptomatic and supportive therapy, yet the lack of specific therapy ways, the treatment of promoting blood circulation for removing blood stasis and dispersing stagnated liver qi for promoting bile flow, based on years of clinical experience of the National Medical master Professor Zhou Zhongying the treatment of chronic liver disease, starting from the theory of damp-heat and blood-stasis-toxin characterized by the chronic liver dieases, Clearing damp-heat and blood-stasis-toxin and dispersing stagnated liver qi totally played the achievements of promoting bile flow. On this basis, the use of the Clinical dialectical addition and subtraction, care is to achieve the banishment of evil spirits, evil to positive safety efficacy.
Objective:through clinical trials to observe the clinical efficacy treatment of promoting blood circulation for removing blood stasis and dispersing stagnated liver qi for promoting bile flow combined with UDCA treatment of primary biliary cirrhosis, the clinical treatment of this disease provide a valid prescription.
Methods:30cases of PBC patients met the inclusion criteria, treatment combinations were randomly divided into control group, main square of the Chinese medicine combined with ursodeoxycholic acid (UDCA) treatment in the control group to the UDCA treatment, treatment for six months, two groups of patients with symptoms and signs, liver function, blood coagulation and other indicators of change in the record before and after treatment, using SPSS13.0for statistical analysis, comparative analysis of efficacy evaluation treatment of promoting blood circulation for removing blood stasis and purging liver and gallbladder with dispersing stagnated liver qi for promoting bile flow is the clinical efficacy of the law.
Result:The treatment group significantly improved the clinical symptoms and signs of patients with fatigue, hypochondriac pain, jaundice, skin itching, role of ALT、ALP、TBil and GGT and other liver function indicators improved significantly in improving the blood coagulation, liver fibrosisthan the control group has obvious advantages.
Conclusion:treatment of promoting blood circulation for removing blood stasis and dispersing stagnated liver qi for promoting bile flow, the clinical efficacy of the treatment of PBC significantly, is worth further study.
研究目的：通过临床试验,观察疏肝利胆活血化瘀法联合UDCA治疗原发性胆汁性肝硬化的临床疗效,为本病的临床治疗提供有效方药。
方法：选择30例符合入选标准的PBC患者,随机分为治疗组和对照组,治疗组予以疏肝利胆活血化瘀为治法的中药联合熊去氧胆酸(优思弗)治疗,对照组予优思弗治疗,疗程为6个月,记录治疗前后两组患者症状体征、肝功能、凝血、肝纤维化等指标的变化,采用SPSS13.0进行统计学处理,对比分析疗效,评价疏肝利胆活血化瘀法的临床疗效。
结果：治疗组能明显改善患者乏力、胁痛、黄疸、皮肤瘙痒等临床症状及体征,对于ALT、ALP、TBil、GGT等肝功能指标改善作用显著,在改善患者凝血功能、肝纤维化等指标方面较对照组具有明显优势。
结论：疏肝利胆活血化瘀法治疗PBC临床疗效显著,值得进一步深入研究。
Background:Primary biliary cirrhosis (PBC) is one of the common diseases of Europe and the United States and other developed countries, the past incidence is relatively low in China, but research shows that China's incidence rate showed an increasing trend, the patients with more than90%35-65year-old female, male and female incidence ratio of1:10, there is significant familial aggregation tendency, visible clinical signs of autoantibodies, elevated immunoglobulin combined immune system diseases, the etiology and pathogenesis of this disease is not clear, the treatment can not betreatment for the cause is still symptomatic and supportive therapy, yet the lack of specific therapy ways, the treatment of promoting blood circulation for removing blood stasis and dispersing stagnated liver qi for promoting bile flow, based on years of clinical experience of the National Medical master Professor Zhou Zhongying the treatment of chronic liver disease, starting from the theory of damp-heat and blood-stasis-toxin characterized by the chronic liver dieases, Clearing damp-heat and blood-stasis-toxin and dispersing stagnated liver qi totally played the achievements of promoting bile flow. On this basis, the use of the Clinical dialectical addition and subtraction, care is to achieve the banishment of evil spirits, evil to positive safety efficacy.
Objective:through clinical trials to observe the clinical efficacy treatment of promoting blood circulation for removing blood stasis and dispersing stagnated liver qi for promoting bile flow combined with UDCA treatment of primary biliary cirrhosis, the clinical treatment of this disease provide a valid prescription.
Methods:30cases of PBC patients met the inclusion criteria, treatment combinations were randomly divided into control group, main square of the Chinese medicine combined with ursodeoxycholic acid (UDCA) treatment in the control group to the UDCA treatment, treatment for six months, two groups of patients with symptoms and signs, liver function, blood coagulation and other indicators of change in the record before and after treatment, using SPSS13.0for statistical analysis, comparative analysis of efficacy evaluation treatment of promoting blood circulation for removing blood stasis and purging liver and gallbladder with dispersing stagnated liver qi for promoting bile flow is the clinical efficacy of the law.
Result:The treatment group significantly improved the clinical symptoms and signs of patients with fatigue, hypochondriac pain, jaundice, skin itching, role of ALT、ALP、TBil and GGT and other liver function indicators improved significantly in improving the blood coagulation, liver fibrosisthan the control group has obvious advantages.
Conclusion:treatment of promoting blood circulation for removing blood stasis and dispersing stagnated liver qi for promoting bile flow, the clinical efficacy of the treatment of PBC significantly, is worth further study.
引文
[1]姚光弼.重视原发性胆汁性肝硬化的临床研究[J].中华肝脏病杂志,2002,10(5)：325-326.
[2]单书健,陈子华.古今名医临证金鉴-黄疸喜鼓胀卷(下)[M].北京：中国中医药出版社,1999：265-405
[3]关幼波.“气血”在辨证施治中的地位和作用[J].中国中西医结合脾胃杂志,1995,3(3)：129--131
[4]关幼波.活血化痰法的应用[J].中国医药学报,1996,11(1)：53—57
[5]姜春华.对肝硬化的认识和治疗[J].新医药学杂志,1975,(1)：40-44
[6]王诗雅,印会河.消臌汤治疗肝性腹胀的临床及机理探讨[J].中国中西医结合杂志,1994,(S1)：32—34
[7]朱良春,陈继明.“复肝丸”治疗早期肝硬化的临床体会[J].上海中医药杂志,1980,(6)：11-12
[8]汪承柏,贺江平,朱纯吾,等.70例肝内胆汁淤积症中医辨证与病理关系的讨论[J].中医杂志,1989,30(1)：25-27.
[9]李林,钟德珍,钟德雄,等.中西医结合诊治胆汁性肝硬化32例临床观察[J].北京中医杂志,2002,21(5)：287-288
[10]叶放,吴勉华,薛博瑜,等.周仲瑛重视慢性肝病湿热瘀毒证治临床经验研究[J].辽宁中医杂志,2007,34(12)：1680—1682
[11]常富业,王永炎,张云岭,等.毒损络脉诠释[J].北京中医药大学学报,2006,29(11)：729-731
[12]常富业,张允岭,郭蓉娟,等.毒损络脉相关病机历史勾勒与诠析[J].北京中医药大学学报,2008,31(2)：79-81
[13]高宪虹.肝硬化辨证分型论治体会[J].中医药临床杂志,2007,19(1)：54-55
[14]徐云生,陈孝银,杨钦河.肝硬化中医治疗浅识[J].四川中医,2003,21(1)：23-24
[15]李佃贵,李刚,刘金里,等.李佃贵以“浊毒”立论治疗肝硬化经验[J].陕西中医,2006,27(11)：1394-1395
[16]赵翠英,刘学华.茵黄合剂治疗妊娠肝内胆汁淤积症的实验研究[J].江苏中医,2000,21(7)：39-41.
[17]苏经格.中药治疗原发性胆汁性肝硬化20例[J].中医杂志,2004,45(7)：528-529
[18]王红霞,金实.金实教授治疗原发性胆汁性肝硬化经验[J].吉林中医药,2011,31(1)：37-38
[19]陈凯佳.邓铁涛五脏相关理论研究的方法和思路探析[J].中医药学刊,2005,23(4)：595-596
[20]刘树农.刘树农医论选[M].上海：上海科学技术出版社,1987：292.
[21]吴智兵,邹立华.彭胜权教授治疗肝硬化经验介绍[J].新中医,2004,36(5)：9-10.
[22]候丽颖,刘友章,季幸姝,等.从肝脾相关理论论治肝硬化[J].新中医,2009,41(8)：114-116.
[23]危北海,张万岱,陈治水,等.肝硬化中西医结合诊治方案[J].现代消化及介入诊疗,2005,10(2)： 119-121.
[24]薛博瑜,顾学兰.肝纤维化的病机认识和辨证论治[J].南京中医药大学学报(自然科学版),2001,17(2)：76-78.
[25]闫秀川,刘成海.肝硬化腹水的中医证型分析[J].中国中医基础医学杂志,2008,14(1)：49-50
[26]董振华,徐慧媛,齐贺彬.原发性胆汁性肝硬化74例中医辨证规律的研究[J].医学研究杂志,2011,40(5)：83—85
[27]张琴,刘平.肝硬化黄疸中医证型研究[J].中西医结合肝病杂志,2001,11(3)：139-141
[28]蒋健,何淼.原发性胆汁性肝硬化的中医证候特点及疗效分析[J].上海中医药大学学报,2003,17(3)：15—17
[29]高宪虹.肝硬化辨证分型论治体会[J].中医药临床杂志,2007,19(1)：54-55.
[30]杨静波,赵长普,李学慧.以中药为主辨证治疗原发性胆汁性肝硬化14例[J].中医研究,2007,20(3)：39-41
[31]韩小平,王守智.辨证分型治疗肝硬化36例临床观察[J].新疆中医药,2008,26(3)：55-56.
[32]王永红.参苓白术散加减治疗肝硬化60例疗效观察[J].河南中医,2008,28(3)：64-65.
[33]苏经格.中药治疗原发性胆汁性肝硬化20例[J].中医杂志,2004,45(7)：528-529
[34]刘鲁明.辨证分型治疗肝硬化臌胀病人172例[J].四川中医,2007,25(7)：59-60.
[35]董振华,徐慧媛,齐贺彬.中西医结合治疗原发性胆汁性肝硬化25例临床观察[J].世界中西医结合杂志,2009,4(3)：185-186,188
[36]周后全.中医辩证治疗156例肝硬化临床疗效观察[J].中国中西医结合脾胃杂志,2000,8(5)：289.
[37]周双男,郭文忠.中西医结合治疗原发性胆汁性肝硬化30例[J].中国中医药现代远程教育,2011,9(17)：48-49
[38]唐海鸿,陈英杰,童光东,等.熊去氧胆酸联合通胆汤对原发性胆汁性肝硬化的治疗作用[J].世界华人消化杂志,2008,16(13)：1417-1424
[39]马作峰.解毒活血扶正法治疗肝硬化308例[J].山西中医,2002,18(2)：13-15.
[40]顾杰,薛惠明.中药治疗原发性胆汁性肝硬化引起的皮肤瘙痒2例[J].上海中医药杂志,2004,38(10)：34-35
[41]张鸣,傅喆暾,黄雄伟.中西结合治疗肝硬化腹水并低蛋白血症床研究[J].中国中医药信息杂志,2007,14(8)：19-20
[42]蒋健,何淼.原发性胆汁性肝硬化的临床特征及中西结合治疗探讨[J].中西医结合学报,2003,
1(2)：99-102
[43]孙凤霞,田德禄,王融冰.中药治疗肝硬化腹水肠源性内毒素症临床研究[J].四床中医,2006,24(1)：53-55
[44]黄伯舜.益气活血软坚利胆法治疗原发性胆汁性肝硬化[J].浙江中医杂志,2005,(7)：306
[45]黄峰,戴侃记,孙晓洁.补阳还五汤加味治疗原发性肝硬化30例[J].陕西中医学院学报,2006,29(5)：39-41
[46]施维群,倪伟.中药脐部贴敷对肝硬化内毒血症的影响[J].中华中医药杂志,2010,25(3)：452-455
[47]席玉红,党中勤,张玉峰,等.以艾灸为主的综合调护法治疗肝病抑郁焦虑症70例[J].河南中医,2011,31(12)：1398-1399
[48]田广俊,陈培琼,池晓玲,等.吴茱萸盐炒热敷腹部治疗肝硬化腹胀疗效观察[J].新中医,2009,41(4)：20-21
[49]王晓,陈欣菊.如意金黄膏封包治疗肝硬化合并自发性腹膜炎58[J].中国中医药信息杂志,2007,14(12)：74
[50]朱小区,吴春明,曹家麟.芒硝敷脐治疗肝硬化腹水42例临床观察[J].海峡药学,2009,21(3)：142-143
[51]黄秀芳.中西医结合三联疗法治疗肝硬变腹水疗效观察[J].辽宁中医杂志,2003,30(10)：841
[52]白厚喜,林森.电针治疗肝硬化患者胃动力障碍[J].实用医药杂志,2006,23(6)：662-663
[53]Ahren EH Jr, Payne MA, Kunkel HG, et al. Primary biliarycirrhosis. Medicine(Baltimore), 1950, 29:299-364.
[54]Ikuno N, M ackay IR, Jp is J, et a 1.. Antim ito chondrial Autoantibody-esa in saliva and sera from patients with primary biliary cirrhosis [J]. J Gastroentero 1 H epato 1,2001(16):1390-1394..
[55]Kita H, Imawari M, Gershwin ME. Cellular immune response inprimary biliary cirrhosis[J]. Hepatol Res, 2004, 28(1):12-17.
[56]Muratori P, Muratori L, Ferrari R, et al.Characterization and clinical impact Of antinuclear antibodies in primary biliary cirrhosis [J].Am J Gastroenterol,2003,98(2):431-4
[57]Jop lin RE, Neuberger JM. I mmunopathology of primary biliary cirrhosis[J]. Gastroentero 1 Hepatol, 1999, 11(6):587-593.
[58]Cornelia D, Albert P, Llorenc C, et al New ELISA for detecting primary biliary cirrhosis -specific antimitochondrial antibodies [J] Clin Chem,2009,55(5):978-985.
[59]王寅虎,杨微,M. Eric Gershwin,廉哲雄.原发性胆汁性肝硬化的细胞免疫学发病机制[J].中华肝病杂志,2011,27(6)：584—587,594.
[60]Ballot E, Bandin O, Chazouilleres O, et al. Immune response to lipopolysaccharide in primary biliary cirrhosis and autoimmune diseases[J]. J Autoimmun,2004,22(2) : 153-158.
[61]Selmi C, Invcrnizzi P, Keeffe EB, et al. Epidemiology and pathogenesis of primary biliary cirrhosis[J]. J Clin Gastroenterol, 2004, 38(3) : 264-271.
[62]Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants [J]. N Engl J Med,2009,360(24):2544 -2555.
[63]范列英,朱烨,仲人前.中国人自身免疫性肝病相关性CT LA-4基因多态性研究[J].中华医学遗传学杂志,2004,21(5)：440—443.
[64]Heathcote EJ. Management of primary biliary cirrhosis[J].Hepatology,2000, 31(4):1005-1013.
[65]Setchell KD, Rodrigues CM, Clerici C, et al. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei[J]. Gastroenterology,1997,112(1):226-235.
[66]Guldutana S, Zimmer G, Imhof M, et al. Molecular aspects of membrane stabilization by ursodeoxycholate [J].Gastroenterology,1993,104 (6):1736-1744.
[67]顾波峰,姚定康.[J].国外医学·消化系疾病分册,2004,24(4)：207-210.
[68]Kita H, Imawari M, Gershwin ME. Cellular immune response inprimary biliary cirrhosis[J]. Hepatol Res, 2004,28(1):12-17.
[69]李芳,李建北,张东明.柴胡的药理研究进展[J].时珍国医国药,2004,15(2)：120-121
[70]王萍,陈青莲.柴胡炮制品小白鼠全血胆碱酯酶活力的影响[J].中药材,2000,23(4)：219-219.
[71]宋景贵,肖正明.柴胡提取物对人肝癌细胞和小鼠S-180肉瘤的抑制作用[J].山东中医药大学学报,2001,25(4)：299-299.
[72]阮金兰,赵钟祥,曾庆忠,等.赤芍化学成分和药理作用的研究进展[J].中国药理学通报,2003,19(9)：965-969.
[73]张伟荣.温郁金注射液对14CCl4代谢物与肝微粒体脂质和蛋白质共价结合的抑制作用研究[J].中医药学报,1990,(2)：46-48.
[74]胡盛军,杨玲,朱清静,等.β-榄香烯对实验性肝纤维化大鼠TGF-β1、α-SMA、Col-1表达的影响[J].世界华人消化杂志,2007,15(12)：1324-1330.
[75]党宁.温郁金二萜类化合物C诱导人肝癌HepG-2细胞凋亡及其机制研究[J].中国医药指南,2012,10(4)：80-82.
[76]谢韬,梁敬钰,刘净.茵陈化学成分和药理作用研究进展[J].海峡药学,2004,16(1)：8-13
[77]陈桂枝,罗德生,王梅娟.茵陈煎剂对大鼠急性化学性肝损伤的保护作用[J].时珍国箕国药,2005,16(7)：617-618
[78]孙旭群,赵新民,杨旭.栀子苷利胆作用实验研究[J].安徽中医学院学报,2004,23(5)：33-36
[79]林蔚,潘竟锵,吕俊华,等.桅子抑制小鼠S_180和肝癌及促进小鼠肝癌细胞凋亡作[J].中国医疗前言,2007,2(8)：4—6
[80]杨铁虹,商澎,梅其炳.当归多糖硫酸酯对凝血和血小板聚集的作用[J].中草药,2002,33(11)：1010-1013.
[81]卿轶,董志.当归多糖对大鼠肝性脑病的预防作用[J].第三军医大学学报,2008,30(23)：2187-2190.
[82]戴维,陈念平,张利强.白芍与当归对阻塞性黄疸大鼠肠道的保护作用[J].山东医学院学报,2008.26(6)：599-600.
[83]Wang H C, Li W, Li J, et al. The Agueous ex tract of a popular herbal nitrient supplement, Angelia sinensis profects mice against Leathal endo to xemia and scpis[J]. Nutritunal Immunology, 2006, 136:360-365.
[84]王浴生,邓文龙,薛春生,等.中药药理与应用(第二版)[M].北京：人民卫生出版社,1998：346
[85]郭雨凡,陈志伟,王鸣军,等.白芍总苷治疗结缔组织病并发胆汁淤积性肝硬化疗效观察[J].苏州 大学学报(医学版),2009,29(6)：1149-1151.
[86]杨洁,蔡刁龙,谭献文.柴胡、红花、川芎中药单体对大鼠肝纤维化论著治疗作用的实验研究[J].临床和实验医学杂志,2009,8(7)：1-3.
[87]费娅丽,黄小民.红花注射液对大鼠内毒素性急性肝损伤保护机制的研究[J].中国中医急症,2009,18(6)：946-948.
[88]聂广,江远,李泽松,等.4种莪术有效成分对肝星状细胞T6基因表达的影响[J].中国中西医结合急救杂志,2005,12(3)：135--139
[2]单书健,陈子华.古今名医临证金鉴-黄疸喜鼓胀卷(下)[M].北京：中国中医药出版社,1999：265-405
[3]关幼波.“气血”在辨证施治中的地位和作用[J].中国中西医结合脾胃杂志,1995,3(3)：129--131
[4]关幼波.活血化痰法的应用[J].中国医药学报,1996,11(1)：53—57
[5]姜春华.对肝硬化的认识和治疗[J].新医药学杂志,1975,(1)：40-44
[6]王诗雅,印会河.消臌汤治疗肝性腹胀的临床及机理探讨[J].中国中西医结合杂志,1994,(S1)：32—34
[7]朱良春,陈继明.“复肝丸”治疗早期肝硬化的临床体会[J].上海中医药杂志,1980,(6)：11-12
[8]汪承柏,贺江平,朱纯吾,等.70例肝内胆汁淤积症中医辨证与病理关系的讨论[J].中医杂志,1989,30(1)：25-27.
[9]李林,钟德珍,钟德雄,等.中西医结合诊治胆汁性肝硬化32例临床观察[J].北京中医杂志,2002,21(5)：287-288
[10]叶放,吴勉华,薛博瑜,等.周仲瑛重视慢性肝病湿热瘀毒证治临床经验研究[J].辽宁中医杂志,2007,34(12)：1680—1682
[11]常富业,王永炎,张云岭,等.毒损络脉诠释[J].北京中医药大学学报,2006,29(11)：729-731
[12]常富业,张允岭,郭蓉娟,等.毒损络脉相关病机历史勾勒与诠析[J].北京中医药大学学报,2008,31(2)：79-81
[13]高宪虹.肝硬化辨证分型论治体会[J].中医药临床杂志,2007,19(1)：54-55
[14]徐云生,陈孝银,杨钦河.肝硬化中医治疗浅识[J].四川中医,2003,21(1)：23-24
[15]李佃贵,李刚,刘金里,等.李佃贵以“浊毒”立论治疗肝硬化经验[J].陕西中医,2006,27(11)：1394-1395
[16]赵翠英,刘学华.茵黄合剂治疗妊娠肝内胆汁淤积症的实验研究[J].江苏中医,2000,21(7)：39-41.
[17]苏经格.中药治疗原发性胆汁性肝硬化20例[J].中医杂志,2004,45(7)：528-529
[18]王红霞,金实.金实教授治疗原发性胆汁性肝硬化经验[J].吉林中医药,2011,31(1)：37-38
[19]陈凯佳.邓铁涛五脏相关理论研究的方法和思路探析[J].中医药学刊,2005,23(4)：595-596
[20]刘树农.刘树农医论选[M].上海：上海科学技术出版社,1987：292.
[21]吴智兵,邹立华.彭胜权教授治疗肝硬化经验介绍[J].新中医,2004,36(5)：9-10.
[22]候丽颖,刘友章,季幸姝,等.从肝脾相关理论论治肝硬化[J].新中医,2009,41(8)：114-116.
[23]危北海,张万岱,陈治水,等.肝硬化中西医结合诊治方案[J].现代消化及介入诊疗,2005,10(2)： 119-121.
[24]薛博瑜,顾学兰.肝纤维化的病机认识和辨证论治[J].南京中医药大学学报(自然科学版),2001,17(2)：76-78.
[25]闫秀川,刘成海.肝硬化腹水的中医证型分析[J].中国中医基础医学杂志,2008,14(1)：49-50
[26]董振华,徐慧媛,齐贺彬.原发性胆汁性肝硬化74例中医辨证规律的研究[J].医学研究杂志,2011,40(5)：83—85
[27]张琴,刘平.肝硬化黄疸中医证型研究[J].中西医结合肝病杂志,2001,11(3)：139-141
[28]蒋健,何淼.原发性胆汁性肝硬化的中医证候特点及疗效分析[J].上海中医药大学学报,2003,17(3)：15—17
[29]高宪虹.肝硬化辨证分型论治体会[J].中医药临床杂志,2007,19(1)：54-55.
[30]杨静波,赵长普,李学慧.以中药为主辨证治疗原发性胆汁性肝硬化14例[J].中医研究,2007,20(3)：39-41
[31]韩小平,王守智.辨证分型治疗肝硬化36例临床观察[J].新疆中医药,2008,26(3)：55-56.
[32]王永红.参苓白术散加减治疗肝硬化60例疗效观察[J].河南中医,2008,28(3)：64-65.
[33]苏经格.中药治疗原发性胆汁性肝硬化20例[J].中医杂志,2004,45(7)：528-529
[34]刘鲁明.辨证分型治疗肝硬化臌胀病人172例[J].四川中医,2007,25(7)：59-60.
[35]董振华,徐慧媛,齐贺彬.中西医结合治疗原发性胆汁性肝硬化25例临床观察[J].世界中西医结合杂志,2009,4(3)：185-186,188
[36]周后全.中医辩证治疗156例肝硬化临床疗效观察[J].中国中西医结合脾胃杂志,2000,8(5)：289.
[37]周双男,郭文忠.中西医结合治疗原发性胆汁性肝硬化30例[J].中国中医药现代远程教育,2011,9(17)：48-49
[38]唐海鸿,陈英杰,童光东,等.熊去氧胆酸联合通胆汤对原发性胆汁性肝硬化的治疗作用[J].世界华人消化杂志,2008,16(13)：1417-1424
[39]马作峰.解毒活血扶正法治疗肝硬化308例[J].山西中医,2002,18(2)：13-15.
[40]顾杰,薛惠明.中药治疗原发性胆汁性肝硬化引起的皮肤瘙痒2例[J].上海中医药杂志,2004,38(10)：34-35
[41]张鸣,傅喆暾,黄雄伟.中西结合治疗肝硬化腹水并低蛋白血症床研究[J].中国中医药信息杂志,2007,14(8)：19-20
[42]蒋健,何淼.原发性胆汁性肝硬化的临床特征及中西结合治疗探讨[J].中西医结合学报,2003,
1(2)：99-102
[43]孙凤霞,田德禄,王融冰.中药治疗肝硬化腹水肠源性内毒素症临床研究[J].四床中医,2006,24(1)：53-55
[44]黄伯舜.益气活血软坚利胆法治疗原发性胆汁性肝硬化[J].浙江中医杂志,2005,(7)：306
[45]黄峰,戴侃记,孙晓洁.补阳还五汤加味治疗原发性肝硬化30例[J].陕西中医学院学报,2006,29(5)：39-41
[46]施维群,倪伟.中药脐部贴敷对肝硬化内毒血症的影响[J].中华中医药杂志,2010,25(3)：452-455
[47]席玉红,党中勤,张玉峰,等.以艾灸为主的综合调护法治疗肝病抑郁焦虑症70例[J].河南中医,2011,31(12)：1398-1399
[48]田广俊,陈培琼,池晓玲,等.吴茱萸盐炒热敷腹部治疗肝硬化腹胀疗效观察[J].新中医,2009,41(4)：20-21
[49]王晓,陈欣菊.如意金黄膏封包治疗肝硬化合并自发性腹膜炎58[J].中国中医药信息杂志,2007,14(12)：74
[50]朱小区,吴春明,曹家麟.芒硝敷脐治疗肝硬化腹水42例临床观察[J].海峡药学,2009,21(3)：142-143
[51]黄秀芳.中西医结合三联疗法治疗肝硬变腹水疗效观察[J].辽宁中医杂志,2003,30(10)：841
[52]白厚喜,林森.电针治疗肝硬化患者胃动力障碍[J].实用医药杂志,2006,23(6)：662-663
[53]Ahren EH Jr, Payne MA, Kunkel HG, et al. Primary biliarycirrhosis. Medicine(Baltimore), 1950, 29:299-364.
[54]Ikuno N, M ackay IR, Jp is J, et a 1.. Antim ito chondrial Autoantibody-esa in saliva and sera from patients with primary biliary cirrhosis [J]. J Gastroentero 1 H epato 1,2001(16):1390-1394..
[55]Kita H, Imawari M, Gershwin ME. Cellular immune response inprimary biliary cirrhosis[J]. Hepatol Res, 2004, 28(1):12-17.
[56]Muratori P, Muratori L, Ferrari R, et al.Characterization and clinical impact Of antinuclear antibodies in primary biliary cirrhosis [J].Am J Gastroenterol,2003,98(2):431-4
[57]Jop lin RE, Neuberger JM. I mmunopathology of primary biliary cirrhosis[J]. Gastroentero 1 Hepatol, 1999, 11(6):587-593.
[58]Cornelia D, Albert P, Llorenc C, et al New ELISA for detecting primary biliary cirrhosis -specific antimitochondrial antibodies [J] Clin Chem,2009,55(5):978-985.
[59]王寅虎,杨微,M. Eric Gershwin,廉哲雄.原发性胆汁性肝硬化的细胞免疫学发病机制[J].中华肝病杂志,2011,27(6)：584—587,594.
[60]Ballot E, Bandin O, Chazouilleres O, et al. Immune response to lipopolysaccharide in primary biliary cirrhosis and autoimmune diseases[J]. J Autoimmun,2004,22(2) : 153-158.
[61]Selmi C, Invcrnizzi P, Keeffe EB, et al. Epidemiology and pathogenesis of primary biliary cirrhosis[J]. J Clin Gastroenterol, 2004, 38(3) : 264-271.
[62]Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants [J]. N Engl J Med,2009,360(24):2544 -2555.
[63]范列英,朱烨,仲人前.中国人自身免疫性肝病相关性CT LA-4基因多态性研究[J].中华医学遗传学杂志,2004,21(5)：440—443.
[64]Heathcote EJ. Management of primary biliary cirrhosis[J].Hepatology,2000, 31(4):1005-1013.
[65]Setchell KD, Rodrigues CM, Clerici C, et al. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei[J]. Gastroenterology,1997,112(1):226-235.
[66]Guldutana S, Zimmer G, Imhof M, et al. Molecular aspects of membrane stabilization by ursodeoxycholate [J].Gastroenterology,1993,104 (6):1736-1744.
[67]顾波峰,姚定康.[J].国外医学·消化系疾病分册,2004,24(4)：207-210.
[68]Kita H, Imawari M, Gershwin ME. Cellular immune response inprimary biliary cirrhosis[J]. Hepatol Res, 2004,28(1):12-17.
[69]李芳,李建北,张东明.柴胡的药理研究进展[J].时珍国医国药,2004,15(2)：120-121
[70]王萍,陈青莲.柴胡炮制品小白鼠全血胆碱酯酶活力的影响[J].中药材,2000,23(4)：219-219.
[71]宋景贵,肖正明.柴胡提取物对人肝癌细胞和小鼠S-180肉瘤的抑制作用[J].山东中医药大学学报,2001,25(4)：299-299.
[72]阮金兰,赵钟祥,曾庆忠,等.赤芍化学成分和药理作用的研究进展[J].中国药理学通报,2003,19(9)：965-969.
[73]张伟荣.温郁金注射液对14CCl4代谢物与肝微粒体脂质和蛋白质共价结合的抑制作用研究[J].中医药学报,1990,(2)：46-48.
[74]胡盛军,杨玲,朱清静,等.β-榄香烯对实验性肝纤维化大鼠TGF-β1、α-SMA、Col-1表达的影响[J].世界华人消化杂志,2007,15(12)：1324-1330.
[75]党宁.温郁金二萜类化合物C诱导人肝癌HepG-2细胞凋亡及其机制研究[J].中国医药指南,2012,10(4)：80-82.
[76]谢韬,梁敬钰,刘净.茵陈化学成分和药理作用研究进展[J].海峡药学,2004,16(1)：8-13
[77]陈桂枝,罗德生,王梅娟.茵陈煎剂对大鼠急性化学性肝损伤的保护作用[J].时珍国箕国药,2005,16(7)：617-618
[78]孙旭群,赵新民,杨旭.栀子苷利胆作用实验研究[J].安徽中医学院学报,2004,23(5)：33-36
[79]林蔚,潘竟锵,吕俊华,等.桅子抑制小鼠S_180和肝癌及促进小鼠肝癌细胞凋亡作[J].中国医疗前言,2007,2(8)：4—6
[80]杨铁虹,商澎,梅其炳.当归多糖硫酸酯对凝血和血小板聚集的作用[J].中草药,2002,33(11)：1010-1013.
[81]卿轶,董志.当归多糖对大鼠肝性脑病的预防作用[J].第三军医大学学报,2008,30(23)：2187-2190.
[82]戴维,陈念平,张利强.白芍与当归对阻塞性黄疸大鼠肠道的保护作用[J].山东医学院学报,2008.26(6)：599-600.
[83]Wang H C, Li W, Li J, et al. The Agueous ex tract of a popular herbal nitrient supplement, Angelia sinensis profects mice against Leathal endo to xemia and scpis[J]. Nutritunal Immunology, 2006, 136:360-365.
[84]王浴生,邓文龙,薛春生,等.中药药理与应用(第二版)[M].北京：人民卫生出版社,1998：346
[85]郭雨凡,陈志伟,王鸣军,等.白芍总苷治疗结缔组织病并发胆汁淤积性肝硬化疗效观察[J].苏州 大学学报(医学版),2009,29(6)：1149-1151.
[86]杨洁,蔡刁龙,谭献文.柴胡、红花、川芎中药单体对大鼠肝纤维化论著治疗作用的实验研究[J].临床和实验医学杂志,2009,8(7)：1-3.
[87]费娅丽,黄小民.红花注射液对大鼠内毒素性急性肝损伤保护机制的研究[J].中国中医急症,2009,18(6)：946-948.
[88]聂广,江远,李泽松,等.4种莪术有效成分对肝星状细胞T6基因表达的影响[J].中国中西医结合急救杂志,2005,12(3)：135--139